Item 1.01 Entry into a Material Definitive Agreement.
As previously disclosed, on
First Closing
The Private Placement is occurring in two tranches. The first closing (the
"First Closing") occurred on
Second Closing
At the closing of the second tranche (the "Second Closing"), subject to
satisfaction of certain closing conditions, including the Company's
stockholders' voting in favor of the Private Placement, Innoviva will purchase
7,717,661 Shares and 7,717,661 Common Warrants for an aggregate purchase price
of approximately
Registration Rights Agreement and Investor Rights Agreement
As part of the First Closing, the Company entered into a registration rights agreement (the "Registration Rights Agreement") and an investor rights agreement (the "Investor Rights Agreement") with Innoviva.
Pursuant to the Registration Rights Agreement, the Company must file a
registration statement on Form S-1 or Form S-3 (the "Shelf Registration
Statement") covering the resale of the securities issued and sold pursuant to
the Securities Purchase Agreement with the
The Investor Rights Agreement provides that for so long as Innoviva and its affiliates hold at least 12.5% of the outstanding shares of Common Stock on a fully-diluted basis, Innoviva shall have the right to designate two (2) directors to the board of directors of the Company (the "Board"), and for so long as Innoviva and its affiliates hold at least 8% but less than 12.5% of the outstanding shares of Common Stock on a fully-diluted basis, Innoviva shall have the right to designate one (1) director to the Board, subject to certain qualifications and conditions in the Investor Rights Agreement. The Investor Rights Agreement also provides for participation rights for Innoviva to participate in future offerings of equity securities by the Company.
The foregoing descriptions of the Registration Rights Agreement and Investor
Rights Agreement, as well as the transactions contemplated therein, do not
purport to be complete and are qualified in their entirety by reference to the
full text of such agreements, copies of which are filed as Exhibits 10.1 and
10.2 to this report, respectively, and incorporated by reference herein. The
Securities Purchase Agreement, a Form of Voting Agreement and a Form of Common
Warrant were filed as Exhibits 10.1, 10.3 and 4.1, respectively, to the Current
Report on Form 8-K, filed by the Company on
Item 3.02 Unregistered Sales of
The information contained above in Item 1.01 related to the Private Placement is
hereby incorporated by reference into this Item 3.02. At the First Closing, the
Company issued 993,139 shares of common stock, and 993,139 Common Warrants, in
exchange for gross proceeds of approximately
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The information relating to the Investor Rights Agreement contained in Item 1.01 above is incorporated by reference herein.
In connection with the First Closing, on
Effective upon the resignations of
Like other non-employee directors, Drs. Schlesinger and Kostas will each be
entitled to receive an annual cash retainer of
In addition, Drs. Schlesinger and Kostas will each be eligible to receive equity
awards in amounts to be determined by the Board pursuant to the Company's 2016
Stock Incentive Plan, as amended (the "Plan"). A copy of the Plan was previously
filed with the
Other than the Investor Rights Agreement, there is no arrangement or understanding between Drs. Schlesinger or Kostas, on the one hand, and any other person, on the other, pursuant to which either was selected as a director of the Company and there are no family relationships between Drs. Schlesinger or Kostas, on the one hand, and any of the Company's directors or executive officers, on the other. There are no transactions to which the Company is a party and in which Drs. Schlesinger or Kostas has a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K.
Item 8.01 Other Events.
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 4.1 Registration Rights Agreement, datedFebruary 12, 2020 , by and between the Company and Innoviva. 4.2 Form of Common Stock Warrant (incorporated herein by reference to Exhibit 4.1 to the Current report on Form 8-K (File No. 001-37544), filed with theSEC onJanuary 29, 2020 ). 10.1 Investor Rights Agreement, datedFebruary 12, 2020 , by and between the Company and Innoviva. 10.2 Securities Purchase Agreement, datedJanuary 27, 2020 , by and between the Company and Innoviva (incorporated herein by reference to Exhibit 10.1 to the Current report on Form 8-K (File No. 001-37544), filed with theSEC onJanuary 29, 2020 ). 10.3 Form of Voting Agreement by and between Innoviva and certain stockholders of the Company (incorporated herein by reference to Exhibit 10.3 to the Current report on Form 8-K (File No. 001-37544), filed with theSEC onJanuary 29, 2020 ). 99.1 Press Release, datedFebruary 13, 2020 .
© Edgar Online, source